Nab-paclitaxel and gemcitabine for the treatment of patients with metastatic pancreatic cancer

Expert Review of Gastroenterology and Hepatology

Volumn 8, Issue 7, 2014, Pages 739-747

  Borazanci, Erkut ^a   Von Hoff, Daniel D ^b  

^a TRANSLATIONAL GENOMICS RESEARCH INSTITUTE   (United States)

^b Virginia G Piper Cancer Center   (United States)

Author keywords

5 fluorouracil; FOLFIRINOX; gemcitabine; nab paclitaxel; pancreatic adenocarcinoma; pancreatic cancer

Indexed keywords

AZACITIDINE; GEMCITABINE; PACLITAXEL; 130-NM ALBUMIN-BOUND PACLITAXEL; ALBUMINOID; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE;

ANEMIA; CANCER COMBINATION CHEMOTHERAPY; CLINICAL EFFECTIVENESS; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; FATIGUE; FEBRILE NEUTROPENIA; HUMAN; KARNOFSKY PERFORMANCE STATUS; LEUKOPENIA; METASTASIS; NEUTROPENIA; NONHUMAN; OVERALL SURVIVAL; PANCREAS CANCER; PERIPHERAL NEUROPATHY; PNEUMONIA; POSTMARKETING SURVEILLANCE; PROGRESSION FREE SURVIVAL; REVIEW; SENSORY NEUROPATHY; SEPSIS; SURVIVAL TIME; THROMBOCYTOPENIA; ADENOCARCINOMA; ANALOGS AND DERIVATIVES; DRUG COMBINATION; MORTALITY; PANCREATIC NEOPLASMS; PHASE 3 CLINICAL TRIAL (TOPIC); SURVIVAL RATE; TREATMENT OUTCOME; TUMOR INVASION;

ADENOCARCINOMA; ALBUMINS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS, PHASE III AS TOPIC; DEOXYCYTIDINE; DRUG THERAPY, COMBINATION; HUMANS; NEOPLASM INVASIVENESS; PACLITAXEL; PANCREATIC NEOPLASMS; PRODUCT SURVEILLANCE, POSTMARKETING; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84906337567     PISSN: 17474124     EISSN: 17474132     Source Type: Journal    
DOI: 10.1586/17474124.2014.925799     Document Type: Review

References (50)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics. CA Cancer J Clin 2014;64(1): 9-29
2. Hidalgo M. Pancreatic cancer. N Engl J Med 2010;362(17):1605-17
3. Jones S, Zhang X, Parsons DW, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 2008;321(5897): 1801-6
4. Stathis A, Moore MJ. Advanced pancreatic carcinoma: current treatment and future challenges. Nat Rev Clin Oncol 2010;7(3): 163-72
5. Carter SK, Comis RL. The integration of chemotherapy into a combined modality approach for cancer treatment. VI. Pancreatic adenocarcinoma. Cancer Treat Rev 1975;2(3):193-214
6. DeCaprio JA, Mayer RJ, Gonin R, Arbuck SG. Fluorouracil and high-dose leucovorin in previously untreated patients with advanced adenocarcinoma of the pancreas: results of a phase II trial. J Clin Oncol 1991;9(12): 2128-33
7. Burris HA 3rd, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997; 15(6):2403-13
8. Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007; 25(15):1960-6
9. Reni M, Cordio S, Milandri C, et al. Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre phase III trial. Lancet Oncol 2005;6(6):369-76
10. Shi S, Yao W, Xu J, et al. Combinational therapy: new hope for pancreatic cancer? Cancer Lett 2012;317(2):127-35
11. Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011;364(19):1817-25
12. Hung SW, Mody HR, Govindarajan R Overcoming nucleoside analog chemoresistance of pancreatic cancer: a therapeutic challenge. Cancer Lett 2012; 320(2):138-49
13. Gemzar® (gemcitabine HCl). Available from: www.accessdata.fda.gov/ drugsatfda-docs/label/2005/020509s033lbl. pdf [Last accessed 3 December 2014]
14. Al-Hajeili M, Azmi AS, Choi M. Nab-paclitaxel: potential for the treatment of advanced pancreatic cancer. Onco Targets Ther 2014;7:187-92
15. Yardley DA. nab-Paclitaxel mechanisms of action and delivery. J Control Release 2013; 170(3): 365-72
16. Ma WW, Hidalgo M. The winning formulation: the development of paclitaxel in pancreatic cancer. Clin Cancer Res 2013; 19(20):5572-9
17. Whitehead RP, Jacobson J, Brown TD, et al. Phase II trial of paclitaxel and granulocyte colony-stimulating factor in patients with pancreatic carcinoma: a Southwest Oncology Group study. J Clin Oncol 1997;15(6):2414-19
18. Lam AP, Sparano JA, Vinciguerra V, et al. Phase II study of paclitaxel plus the protein kinase C inhibitor bryostatin-1 in advanced pancreatic carcinoma. Am J Clin Oncol 2010;33(2):121-4
19. Ibrahim NK, Desai N, Legha S, et al. Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. Clin Cancer Res 2002;8(5): 1038-44
20. Sparreboom A, Scripture CD, Trieu V, et al. Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (Taxol). Clin Cancer Res 2005;11:4136-43
21. Kremer P, Hartung G, Bauder-Wust U, et al. Efficacy and tolerability of an aminopterin-albumin conjugate in tumor-bearing rats. Anticancer Drugs 2002;13:615-23
22. Simionescu M, Gafencu A, Antohe F. Transcytosis of plasma macromolecules in endothelial cells: a cell biological survey. Microsc Res Tech 2002;57:269-88
23. Maeda H, Wu J, Sawa T, et al. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release 2000;65: 271-84
24. Desai N, Trieu V, Yao Z, et al. Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin Cancer Res 2006;12:1317-24
25. Shao H, Tang H, Salavaggione OE, et al. Improved response to nab-paclitaxel compared with cremophor-solubilized paclitaxel is independent of secreted protein acidic and rich in cysteine expression in non-small cell lung cancer. J Thorac Oncol 2011;6:998-1005
26. Desai N, Trieu V, Damascelli B, Soon-Shion P. SPARC expression correlates with tumor response to albumin-bound paclitaxel in head and neck cancer patients. Transl Oncol 2009;2:59-64
27. Von Hoff DD, Ramanathan RK, Borad MJ, et al. Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. J Clin Oncol 2011;29(34):4548-54
28. Frese KK, Neesse A, Cook N, et al. nab-Paclitaxel potentiates gemcitabine activity by reducing cytidine deaminase levels in a mouse model of pancreatic cancer. Cancer Discov 2012;2(3):260-9
29. ABRAXANE® for injectable suspension. Available from: www.accessdata.fda.gov/drugsatfda-docs/label/2013/021660s037lbl. pdf [Last accessed 3 December 2014]
30. Von Hoff DD, Ervin TJ, Arena FP, et al. Randomized phase III study of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic adenocarcinoma of the pancreas (MPACT). Presented at: 2013 Gastrointestinal Cancers Symposium; 24-26 January 2013; San Francisco, CA, USA
31. Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 2013;369(18):1691-703
32. David G, Robert Hassan EM, Pascal H, et al. Updated survival from a randomized phase III trial (MPACT) of nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients (pts) with metastatic adenocarcinoma of the pancreas. Presented at: 2014 Gastrointestinal Cancers Symposium; 16-18 January 2014; San Francisco, CA, USA
33. Celgene. Available from: http://ir.celgene. com/releasedetail.cfm? releaseid=821049 [Last accessed 3 December 2014]
34. PRNewswire. Available from: www.prnewswire.com/news-releases/specialised- therapeutics-australia-receives-therapeutic-goods-administration-approval-for- abraxaner-in-combination-with-gemcitabine-for-first-line-treatment-of- metastatic-pancreatic-cancer-250767031.html [Last accessed 3 December 2014]
35. Huguet F, Girard N, Guerche CS, et al. Chemoradiotherapy in the management of locally advanced pancreatic carcinoma: a qualitative systematic review. J Clin Oncol 2009;27(13):2269-77
36. Liao WC, Chien KL, Lin YL, et al. Adjuvant treatments for resected pancreatic adenocarcinoma: a systematic review and network meta-analysis. Lancet Oncol 2013; 14(11):1095-103
37. Heinemann V, Reni M, Ychou M, et al. Tumour-stroma interactions in pancreatic ductal adenocarcinoma: rationale and current evidence for new therapeutic strategies. Cancer Treat Rev 2014; 40(1): 118-28
38. Olowokure O, Torregroza-Sanchez MP, Bedoya-Apraez ID. Gemcitabine plus Nab-Paclitaxel with chemoradiation in locally advanced pancreatic cancer (LAPC). J Gastrointest Oncol 2013;4(2):E16-18
39. MacKenzie S, Zeh H, McCahill LE, et al. A pilot phase II multicenter study of nab-paclitaxel (Nab-P) and gemcitabine (G) as preoperative therapy for potentially resectable pancreatic cancer (PC). Presented at: 2013 ASCO Annual Meeting; 31 May-4 June January 2013; Chicago, USA
40. Clinical Trails.gov. Available from: www.clinicaltrials.gov/ct2/results? term=nabpaclitaxel+gemcitabine&recr [Last accessed 23 March 2014]
41. Portal A, Pernot S, Siauve N, et al. Sustained response with gemcitabine plus Nab-paclitaxel after folfirinox failure in metastatic pancreatic cancer: report of an effective new strategy. Clin Res Hepatol Gastroenterol 2014;38(2):e23-6
42. Peddi PF, Cho M, Wang J, et al. Nab-paclitaxel monotherapy in refractory pancreatic adenocarcinoma. J Gastrointest Oncol 2013;4(4):370-3
43. Borazanci E, Schroeder K, Jameson G, et al. Reinitiating nab-paclitaxel plus gemcitabine in patients with advanced pancreatic cancer. Presented at: 2014 Gastrointestinal Cancers Symposium. 16-18 January 2014; San Francisco, CA, USA
44. Chugh R, Sangwan V, Patil SP, et al. A preclinical evaluation of Minnelide as a therapeutic agent against pancreatic cancer. Sci Transl Med 2012;4(156):1-10
45. Provenzano PP, Cuevas C, Chang AE, et al. Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell 2012; 21(3):418-29
46. Salo-Mullen EE, O'Reilly EM, Kelsen DP, et al. Identification of germline genetic mutations in patients with pancreatic adenocarcinoma. Presented at: 2013 Gastrointestinal Cancers Symposium. 24-26 January 2013; San Francisco, CA, USA
47. Rustgi AK. Familial pancreatic cancer: genetic advances. Genes Dev 2014;28(1):1-7
48. Lee JM, Ledermann JA, Kohn EC. PARP inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies. Ann Oncol 2014;25(1):32-40
49. Bajor DL, Vonderheide RH. Cracking the stone: combination vaccination and CTLA-4 blockade in pancreatic cancer. J Immunother 2013;36(7):362-4
50. Le DT, Wang-Gillam A, Picozzi V, et al. A phase 2, randomized trial of GVAX pancreas and CRS-207 immunotherapy versus GVAX alone in patients with metastatic pancreatic adenocarcinoma: Updated results. Presented at: 2014 Gastrointestinal Cancers Symposium; 16-18 January 2014; San Francisco, CA, USA